Formally established by the institution in 2006 to address the growing demand for bioinformatics expertise at Mayo Clinic, the Bioinformatics Core Shared Resource (BIC) is a new shared resource of the Cancer Center. The mission of the Shared Resource is to assist Mayo Clinic Cancer Center (MCCC) investigators in leveraging intramural and extramural sources of biological information to promote discoveries that will impact patient care. To this end, the BIC offers a suite of services to support investigators with the manipulation, preprocessing, and interpretation of genomics, microarray, and proteomics data. These services include: sequence analysis and comparative genomics;gene and SNP selection for association studies;data parsing and formatting;gene ID conversion, biological pathway and networks analysis;data preprocessing;including quality control;and management and education regarding public and local databases and bioinformatics applications. BIC has assembled a team of 13 computer scientists and 12 bioinformatics experts who work collaboratively with biostatisticians to provide analytical support to investigators at all three Mayo campuses. NCI related goals for bioinformatics is assured by dedicated Shared Resource support for the evaluation and integration of caBIG projects into Mayo's infrastructure. BIC provides critical 'value-add'to MCCC investigators in providing (i) investigator support during planning and execution of high throughput experiments;(ii) development of bioinformatics tools and education programs;and (iii) infrastructure for experimental techniques and analytical methods validation, including quality control workflows for genotyping data, preprocessing workflows for gene expression profiles, validation of copy number variation, and high throughput sequencing;and platforms for data integration and mining. Over the past year, BIC has supported 36 MCCC investigators, accounting for more than 50% of the Shared Resource's total usage, and offered 22 classes and training programs attended by more than 40 MCCC investigators and personnel.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-35
Application #
7945065
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-17
Project End
2014-02-28
Budget Start
2009-04-17
Budget End
2010-02-28
Support Year
35
Fiscal Year
2009
Total Cost
$245,021
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066

Showing the most recent 10 out of 1129 publications